Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY StudyMerve Sivridaş, Luc J. J. Derijks, Rob H. Creemers et al.|Pharmaceutics|2023Cited by 17
Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease PatientsSofia A. W. van Moorsel, Dennis R. Wong, Adriaan A. van Bodegraven et al.|Therapeutic Drug Monitoring|2022Cited by 6
A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patientsDebbie S. Deben, Dennis R. Wong, Rob H. Creemers et al.|Scientific Reports|2022Cited by 3
Implications of Tioguanine Dosing in IBD Patients with a TPMT DeficiencyDebbie S. Deben, Dennis R. Wong, Luc J. J. Derijks et al.|Metabolites|2023Cited by 1
P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patientsDebbie S. Deben, A Van Bodegraven, Rob H. Creemers et al.|Journal of Crohn s and Colitis|2022Cited by 0